Wang Xiaodong, DIR, reported an open-market or private sale at BeOne Medicines Ltd. involving 3419.000000 shares for an estimated $1244746.78. Reported holdings after the transaction were 17310.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
No officer title
These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
These securities are held by Wang Investment LLC, of which 99% of the limited liability company interests are owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a tr…
These securities are held by the spouse of the Reporting Person.
Each American Depositary Share represents 13 Ordinary Shares.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.94 to $357.07, inclusive. The Reporting Person has provided to t…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.11 to $359.01, inclusive. The Reporting Person has provided to t…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.65 to $361.64, inclusive. The Reporting Person has provided to t…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.66 to $362.65, inclusive. The Reporting Person has provided to t…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.67 to $363.59, inclusive. The Reporting Person has provided to t…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.67 to $364.62, inclusive. The Reporting Person has provided to t…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.13 to $366.12, inclusive. The Reporting Person has provided to t…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.13 to $367.12, inclusive. The Reporting Person has provided to t…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.13 to $367.25, inclusive. The Reporting Person has provided to t…
The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject…
0 other filings
0 recent txs